House’s insulin pricing provisions need to be included in Build Back Better Act
The Endocrine Society urges the Senate to protect the insulin affordability provisions included in the Build Back Better Act and move quickly to pass this crucial legislation.
We implore all Senators to ensure these provisions are not scaled back. The Build Back Better Act represents the best opportunity to address the price of insulin. Millions of Americans cannot wait any longer for a solution.
The Build Back Better Act, which was passed by the House, would cap insulin co-pays at $35 per month for Medicare beneficiaries and those on private insurance.It isalso critical that the legislation include individuals covered by private insurance. These individuals face insulin price hikes just like Medicare beneficiaries. Imposing limitations on this provision would perpetuate limited access to affordable insulin for people living with diabetes.
The Build Back Better Act would institute an inflation cap ensuring that the price of insulin doesn’t increase faster than inflation. In addition, the bill would give the government authority to negotiate the price of certain drugs, including insulin.
For millions of Americans living with diabetes, including all people living with type 1 diabetes, insulin is a life-saving drug that must be taken to control blood sugar. Although insulin has been available for 100 years, its price continues to increase and has nearly tripled over the past 15 years.
The Endocrine Society has prioritized the need for affordable insulin for years. Our members are dedicated to educating Congress about the challenges people with diabetes face in accessing affordable insulin. We have shared policy recommendations, testimony, and a collection of patient stories illustrating that people with diabetes continue to suffer due to the high price of insulin.
The Senate must move quickly to pass this legislation, which would make insulin more affordable for millions of Americans with diabetes.
About the Endocrine Society
Endocrinologists are at the core of solving the most pressing health problems of our time, including diabetes, obesity, infertility, bone health, and hormone-related cancers. The Endocrine Society is the largest global organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
With more than 18,000 members in 133 countries, the Society serves as the voice of the endocrine field. Through its renowned journals and ENDO, the world's largest endocrine meeting, the Society accelerates hormone research, advances clinical excellence in endocrinology, and advocates for evidence-based policies on behalf of the global endocrine community. To learn more, visit our online newsroom.
Colleen Williams Associate Director, Communications and Media Relations Phone: (202)-971-3611 [email protected]
Jenni Glenn Gingery Director, Communications and Media Relations Phone: (202)-971-3655 [email protected]
The Endocrine News podcast brings you the latest research and clinical advances from experts in the field, whether you are in your car, office, or out for a run.
Our top-ranked peer-reviewed journals are among the first to publish major developments and discovery milestones.
